Merck (MRK) Announces Letermovir Phase 3 Met Primary Endpoint in Bone Marrow Transplant Patients
Go back to Merck (MRK) Announces Letermovir Phase 3 Met Primary Endpoint in Bone Marrow Transplant PatientsMerck & Co. (NYSE: MRK) | Delayed: 125.37 +0.31 (0.25%) | |||||
---|---|---|---|---|---|---|
Previous Close | $125.06 | 52 Week High | $65.46 | |||
Open | $125.67 | 52 Week Low | $47.97 | |||
Day High | $126.19 | P/E | 85.29 | |||
Day Low | $124.71 | EPS | $1.47 | |||
Volume | 6,122,845 |